Standard treatment of ulcerative colitis

Digestive Diseases

Volumn 21, Issue 2, 2003, Pages 157-167

  Gionchetti, Paolo ^a,c   Rizzello, Fernando ^a   Habal, Flavio ^b   Morselli, Claudia ^a   Amadini, Cristina ^a   Romagnoli, Rossella ^a   Campieri, Massimo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

5 Aminosalicylic acid; Cyclosporine; Immunosuppressors; Infliximab; Topical steroids; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; AZATHIOPRINE; BALSALAZIDE; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; FLUTICASONE; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; OLSALAZINE; PREDNISOLONE; PREDNISOLONE 3 SULFOBENZOATE; PROBIOTIC AGENT; RIFAMPICIN; SALAZOSULFAPYRIDINE; TIXOCORTOL PIVALATE; TOBRAMYCIN; VANCOMYCIN;

ALLERGIC REACTION; BIOLOGICAL MONITORING; BONE MARROW SUPPRESSION; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENCY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GINGIVITIS; HEALTH CARE PERSONNEL; HEPATITIS; HERPES ZOSTER; HOSPITALIZATION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; LOW DRUG DOSE; META ANALYSIS; NAUSEA; NEOPLASM; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; PANCREATITIS; PARESTHESIA; PREDICTION; PRIORITY JOURNAL; PROCTOCOLECTOMY; REMISSION; REVIEW; SEIZURE; SIDE EFFECT; STANDARDIZATION; STATISTICAL SIGNIFICANCE; STEROID THERAPY; SYSTEMIC DISEASE; TOXICITY; TREATMENT OUTCOME; ULCERATIVE COLITIS; VOMITING;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MESALAMINE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX;

EID: 0142156581     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073247     Document Type: Review

References (75)

1. Farrokh-Yar F, Swarbrick ET, Grace RH, et al: Excellent outcome of first attack of ulcerative colitis in three regional cohorts (abstract). Gastroenterology 1999;116:A711.
2. Williams CN, Haber G, Aquino JA: Double-blind placebo-controlled evaluation of 5-ASA suppositories in active proctitis and measurement of extent of spread using 99m-Tc labelled 5-ASA suppositories. Dig Dis Sci 1987;32:71S-75S.
3. Jay M, Beihn RM, Digenis GA, et al: Disposition of radiolabelled suppositories in humans. J Pharm Pharmacol 1985;37:266-268.
4. Campieri M, Gionchetti P, Belluzzi A, et al: 5-aminosalicylic acid as enemas or suppositories in distal ulcerative colitis. J Clin Gastroenterol 1988;10:406-409.
5. Gionchetti P, Rizzello F, Venturi A, et al: Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum 1998;41:93-97.
6. Wilding IR, Kenyon CJ, Chauhan S, et al: Colonic spreading of a non-chlorofluorocarbon mesalazine rectal foam enema in patients with quiescent ulcerative colitis. Aliment Pharmacol Ther 1995;9:161-166.
7. Van Bodegraven AA, Bower RO, Lourens J, et al: Distribution of mesalazine enemas in active and quiescent ulcerative colitis. Aliment Pharmacol Ther 1996;10:327-332.
8. Campieri M, Corbelli C, Gionchetti P, et al: Spread and distribution of 5-ASA colonic foam and 5-ASA enemas in patients with ulcerative colitis. Dig Dis Sci 1992;37:1890-1897
9. Gionchetti P, Venturi A, Rizzello F, et al: Retrograde colonic spread of a new mesalazine rectal enema in patients with distal ulcerative colitis. Aliment Pharmacol Ther 1997;11:679-684.
10. Campieri M, Paoluzi P, D'Albasio G, et al: Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis: A multicentre comparative trial with 5-ASA enema. Dig Dis Sci 1993;38;1843-1850.
11. Gionchetti P, Ardizzone S, Benvenuti ME, et al: A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: A randomized controlled trial. Aliment Pharmacol Ther 1999;13:381-388.
12. Marshall JK, Irvine EJ: Rectal aminosalicylate therapy for distal ulcerative colitis: A meta-analysis. Aliment Pharmacol Ther 1995;9: 293-300.
13. Marshall JK, Irvine EJ: Rectal corticosteroids versus alternative treatments in ulcerative colitis: A meta-analysis. Gut 1997;40:775-781.
14. Cohen RD, Douglas M, Woseth BA, et al: A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000;95:1263-1276.
15. Sutherland LR, May GR, Shaffer EA: Sulfasalazine revisited: A meta-analysis of 5-aminosali-cylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993;118:540-549.
16. Safdi M, De Micco M, Sninsky C, et al: A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997;92:1867-1871.
17. Vecchi M, Meucci G, Gionchetti P, et al: Oral versus combination mesalazine therapy in active ulcerative colitis: A double-blind, double-dummy, randomized multicentre trial. Aliment Pharmacol Ther 2001;15:251-256.
18. Sutherland LR, Roth DE, Beck PL: Alternatives to sulfasalazine: A meta-analysis of 5-ASA in the treatment of ulcerative colitis. Inflamm Bowel Dis 1997;3:65-78.
19. Courtney MG, Nunes DP, Bergin CF, et al: Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet 1992;339:1279.
20. Green JR, Lobo AJ, Holdsworth CD, et al: Balsalazide is more efective and better tolearted than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology 1998;114:15-22.
21. Thiesen A, Thomson AB: Review article: older systemic and topical glucocorticosteroids and the gastrointestinal tract. Aliment Pharmacol Ther 1996;10:487-496.
22. Lofberg R, Ostergaard Thomsen O, Langholz E, et al: Budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1994;8:623-629.
23. Campieri M, Cottone M, Miglio F, et al: Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis. Aliment Pharmacol Ther 1998;12:361-366.
24. Campieri M, Adamo S, Valpiani D, D'Arienzo A, D'Albasio G, Pitzalis M, Cesari P, Casetti T, Castiglione GN, Rizzello F, Manguso F, Varoli G, Gionchetti P: Oral beclomethasone dipropionate in the treatment of estensive and left-sided active ulcerative colitis: A multicentre randomised study. Aliment Pharmacol Ther 2003;in press.
25. Rizzello F, Gionchetti P, D'Arienzo A, Manguso F, Di Matteo G, Annese V, Valpiani D, Casetti T, Adamo S, Prada A, Castiglione G.N, Varoli G, Campieri M: Oral beclomethasone dipropionate in the treatment of active ulcerative colitis: A double-blind placebo-controlled study. Aliment Pharmacol Ther 2002;16:1109-1116.
26. Baron JH: Outpatients treatment of ulcerative colitis. Br Med J 1962;ii:441-444.
27. Kornbluth A, Sachar DB: Ulcerative colitis practice guidelines in adults. Am J Gastroenterology 1997;92:204-211.
28. Kirk AP, Lennard-Jones JE: Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J 1982;284:1291-1292.
29. Rosenberg JL, Wall AJ, Settles RH, et al: A controlled trial of azathioprina in the treatment of chronic ulcerative colitis. Gastroenterology 1973;64:793-801.
30. Truelove SC, Witts LJ: Cortisone in ulcerative colitis: preliminary report on a therapeutic trial. BMJ 1954;2:375-378.
31. Truelove SC, Jewell DP: Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974;i:1067-1070.
32. Baron JH, Conell AM, Lennard-Jones JE: Variation between observers in describing mucosal appearance in proctocolitis. Br Med J 1964;i:89-92.
33. Carbonnel F, Lavergne A, Lèmann M, et al: Colonoscopy of acute colitis: A safe and reliable tool for assessment of severity. Dig Dis Sci 1994;39:1550-1557.
34. Travis SPL, Farrant JM, Ricketts C, et al: Predicting outcome in severe ulcerative colitis. Gut 1996;38:905-910.
35. Lennard-Jones JE, Ritchie JK, Hilder W, et al: Assessment of severity in colitis: a preliminary study. Gut 1975;16:579-584.
36. Caprilli R, Vernia P, Latella G, et al: Early recognition of toxic megacolon. J Clin Gastroenterol 1987;9:160-164.
37. Chew CN, Nolan DJ, Jewell DP: Small bowel gas in severe ulcerative colitis. Gut 1991;32:1535-1537.
38. Edward FC, Truelove SC: The course and prognosis of ulcerative colitis. Gut 1963;4:299-315.
39. Jarnerot G, Rolny P, Sandberg-Gertzen H: Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985;89:1005-1013.
40. Kaplan HP, Portnoy HJ, Binder HJ, et al: A controlled evaluation of intravenous adrenocorticotropin hormone and hydrocortisone in the treatment of acute colitis. Gastroenterology 1975;69:91-95.
41. Faubion WA, Loftus EV, Harmsen WS, et al: The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study. Gastroenterology 2001;121;255-260.
42. Dickinson RJ, Ashton MG, Axon ATR, et al: Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. Gastroenterology 1980;79:1199-1204.
43. Chapman RW, Selby WS, Jewell DP: Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986;27:1210-1212.
44. Mantzaris GJ, Petraki K, Archavlis E, et al: A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol 2001;36:971-974.
45. Dickinson RJ, O'Connor HJ, Pinder I, et al: Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbation of idiopathic colitis. Gut 1985;26:1380-1384.
46. Burke DA, Axon ATR, Clayden SA, et al: The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 1990;4:123-129.
47. Gionchetti P, Rizzello F, Ferrieri A, Venturi A, Brignola C, Ferretti M, Peruzzo S, Miglioli M, Campieri M: Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid treatment: A double blind, placebo-controlled trial. Dig Dis Sci 1999;44:1220-1221.
48. Turunen UM, Farkkila MA, Hakala K, et al: Long-term treatment of ulcerative colitis with cirpofloxacin: A prospective, double-blind, placebo-controlled study. Gastroenterology 1998;115:1072-1078.
49. Lichtiger S, Present D, Kornbluth A, et al: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-1845.
50. Actis GC, Ottobrelli A, Pera A, et al: Continously infused cyclosporine at low dose is sufficient to avoid emergency colectomy in acute attacks of ulcerative colitis without the need for high-dose steroids. J Clin Gastroenterol 1993;17:10-13.
51. Actis GC, Aimo G, Priolo G et al: Efficacy and efficiency of oral microemulsion cyclosporine versus intravenous and of gelatin cyclosporine in the treatment of severe steroid-refractory ulcerative colitis: An open retrospective trial. Inflamm Bowel Dis 1998;4:276-279.
52. Chey W: Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis 2001;1:s30-33.
53. Sands ES, Tremaine WJ, Sandborne WJ, et al: Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study. Inflamm Bowel Dis 2001;7:83-88.
54. Kohn A, Prantera C, Pera A, et al: Anti-tumor necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: Result of an open study on 13 patients. Dig Liv Dis 2002;34:626-630.
55. Probert CSJ, Hearing SD, Schreiber S, et al: Infliximab in steroid-resistant ulcerative colitis: A randomised controlled trial (abstract). Gastroenterology 2002:772.
56. Misiewicz JJ, Lennard-Jones JE, Connell Am, et al: Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1965;i:185-188.
57. Dissanayake AS, Truelove SC: A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin). Gut 1973;14:923-926.
58. Azad-khan AK, Piris J, Truelove SC: An experiment to determine the active therapeutic moiety of sulphalasazine. Lancet 1977;ii:892-895.
59. Sutherland L, Roth D, Beck P, et al: Oral 5-aminosalicylic acid for maintaining remission in ulcerative colitis. Cochrane Database Syst Rev 2000;2:CD000544.
60. Langholz E, Munkholm P, Davidsen M, et al: Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992;103:1444-1451.
61. Ardizzone S, Petrillo M, Imbesi V, et al: Is maintenance therapy always necessary for patients with ulcerative colitis in remission? Aliment Pharmacol Ther 1999;13:373-379.
62. Marshall JK, Irvine EJ: Putting rectal 5-aminosalicylic acid in its place: The role in distal ulcerative colitis. Am J Gastroenterol 2000;95:1628-1636.
63. Stack WA, Long RG, Hawkey CJ: Short- and long-term outcome of patients treated with cyclosporin for severe ulcerative colitis. Aliment Pharmacol Ther 1998;12:973-978.
64. Cohen RD, Stein R, Hanauer SB: Intravenous cyclosporin in ulcerative colitis: A five-year experience. Am J Gastroenterol 1999;94:1587-1592.
65. Fernàndez-Bañares F, Bertran X, Esteve-Comas M, et al: Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporin in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 1996;91:2498-2499.
66. Actis GC, Bresso F, Astegiano A, et al: Safety and efficacy of azathioprine in the maintenance of ciclosporin-induced remission of ulcerative colitis. Aliment Pharmacol Ther 2001;15:1307-1311.
67. Connell WR, kinlen LJ, Ritchie JK, et al: Long term risk of neoplasia in patients treated with azathioprine for inflammatory bowel disease. Lancet 1994;343:1249-1252.
68. Connell WR, Kamm MA, Lennard-Jones JE, et al: Bone marrow toxicity from azathioprine: twenty-seven year experience in inflammatory bowel disease. Gut 1993,34:1081-1085.
69. Alstead EM, Ritchie JK, Lennard-Jones JE, et al: Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 990;99:443-446.
70. Schaafsma G: State of the art concerning probiotic strains in milk products. IDF Nutr Newslett 1996;5:23-24.
71. Kruis W, Schutz E, Fric P, et al: Double-blind comparison of an oral Echerichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853-858.
72. Rembacken BJ, Snelling AM, Hawkey PM, et al: Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial. Lancet 1999;354:635-639.
73. Kruis W, Fric P, Stolte S: Maintenance of remission in ulcerative colitis is equally effective with Escherichia coli nissle 1917 and with a standard mesalamine (abstract). Gastroenterology 2001;12:A127.
74. Venturi A, Gionchetti P, Rizzello F, et al: Impact on the faecal flora composition of a new probiotic preparation. Preliminary data on maintenance treatment of patients with ulcerative colitis (UC) intolerant or allergic to 5-aminosalycilic acid (5-ASA). Aliment Pharmacol Ther 1999;13:1103-1108.
75. Fernández-Bañares F, Hinojosa J, Sanchez-Lombraña JL, et al: Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Am J Gastroenterol 1999;94:427-433.